AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28178436 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple nerve blocks
Number of subjects: 90
Study 28178436 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 90
Study 28178436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve blocks)
Number of subjects: 90
Study 28178640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) in combination with abiraterone and prednisone (AP)
Number of subjects: 9
Study 28178640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib
Number of subjects: 9
Study 28178885 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic reference region extraction methodology
Number of subjects: 0
Study 28178929 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent variable mixture model
Number of subjects: 653
Study 28178929 — intervention group
Group type: COMPARATOR
Intervention: Linear model
Number of subjects: 653
Study 28179030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (0.35 mg/kg with intrapatient dose escalation up to 5 mg/kg, once weekly)
Number of subjects: 9
Study 28179030 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n=21)
Number of subjects: 9
Study 28179222 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal macronutrient intake during pregnancy
Number of subjects: 0
Study 28179273 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation-free conditioning regimen with a T-cell-depleted graft including busulfan, cyclophosphamide, fludarabine, and rabbit anti-thymocyte globulin.
Number of subjects: 45
Study 28179405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid procalcitonin (CSF PCT)
Number of subjects: 143
Study 28179405 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (serum PCT)
Number of subjects: 143
Study 28179405 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional biomarkers
Number of subjects: 143
Study 28179416 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare during infancy
Number of subjects: 666
Study 28179416 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple caregivers
Number of subjects: 666
Study 28179439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ATP
Number of subjects: 40
Study 28179439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled AMP
Number of subjects: 40
Study 28179492 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicator Amino Acid-Derived Estimate of Dietary Protein Requirement
Number of subjects: 0
Study 28179648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (DI) - very-low-calorie diet (VLCD, 500 kcal/day) for 5 weeks
Number of subjects: 15
Study 28181118 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutemetamol F 18 Injection (185 MBq)
Number of subjects: 70
Study 28181260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab (RN316/PF-04950615)
Number of subjects: 0
Study 28181260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab (RN316/PF-04950615) with concomitant statins
Number of subjects: 0
Study 28181668 — intervention group
Group type: EXPERIMENTAL
Intervention: NSI-189
Number of subjects: 0
Study 28181933 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe intraoperative hyperglycemia (SIH, blood glucose ≥180 mg/dL)
Number of subjects: 224
Study 28181933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 224
Study 28182762 — intervention group
Group type: EXPERIMENTAL
Intervention: High 2'FL concentration (1880-2460 mg/L)
Number of subjects: 50
Study 28182762 — intervention group
Group type: COMPARATOR
Intervention: Low 2'FL concentration (12-42 mg/L)
Number of subjects: 50
Study 28183321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pertuzumab, trastuzumab, and docetaxel
Number of subjects: 0
Study 28183321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 0
Study 28183321 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel
Number of subjects: 0
Study 28183321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 0
Study 28183321 — intervention group
Group type: COMPARATOR
Intervention: Non-trastuzumab-treated group
Number of subjects: 0
Study 28183321 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab-containing groups
Number of subjects: 0
Study 28183354 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid expansion (ACA)
Number of subjects: 275000
Study 28183354 — intervention group
Group type: EXPERIMENTAL
Intervention: States that expanded Medicaid
Number of subjects: 275000
Study 28183354 — intervention group
Group type: COMPARATOR
Intervention: States that did not expand Medicaid
Number of subjects: 275000
Study 28183713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination targeting native receptors
Number of subjects: 0
Study 28185086 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based system (self-screening, patient education, self-referral)
Number of subjects: 20
Study 28185086 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based system
Number of subjects: 20
Study 28185285 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in health-related research studies
Number of subjects: 18
Study 28185288 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/day for 9 or more days prior to surgery)
Number of subjects: 50
Study 28185288 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 50
Study 28185875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a median dose of 24 Gy in 3 fractions
Number of subjects: 94
Study 28185875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with androgen deprivation (AD) in 34 patients
Number of subjects: 94
Study 28185875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 94
Study 28186982 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated Trastuzumab (bTrast)
Number of subjects: 0
Study 28186982 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated Pertuzumab (bPert)
Number of subjects: 0
Study 28186982 — intervention group
Group type: EXPERIMENTAL
Intervention: AvidinOX anchorage with biotinylated antibodies
Number of subjects: 0
Study 28187404 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentized estrogen (12cH, 18cH and 24cH) administered twice daily per oral route for 24 weeks
Number of subjects: 50
Study 28187404 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentized estrogen (12cH, 18cH and 24cH)
Number of subjects: 50
Study 28187404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28187733 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed HRQoL tool
Number of subjects: 500
Study 28187733 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled breath temperature (EBT)
Number of subjects: 500
Study 28187733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function tests
Number of subjects: 500
Study 28187733 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 500
Study 28187733 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomics, transcriptomics, proteomics
Number of subjects: 500
Study 28187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) assessment for cardiomyopathy (21%)
Number of subjects: 62456
Study 28187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) assessment for myocardial viability (16%)
Number of subjects: 62456
Study 28187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) stress perfusion for chest pain syndromes (16%)
Number of subjects: 62456
Study 28187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) evaluation of etiology of arrhythmias or planning of electrophysiological studies (15%)
Number of subjects: 62456
Study 28187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of gadolinium-based contrast media in CMR studies (95%)
Number of subjects: 62456
Study 28187747 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Primary Care (CPC) initiative
Number of subjects: 21
Study 28187747 — intervention group
Group type: EXPERIMENTAL
Intervention: CFIR framework
Number of subjects: 21
Study 28187771 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E)
Number of subjects: 9
Study 28187771 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH stimulation
Number of subjects: 9
Study 28187771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic, unopposed E
Number of subjects: 9
Study 28187933 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal bioimpedance (BIA) with the ViScan device
Number of subjects: 140
Study 28187933 — intervention group
Group type: COMPARATOR
Intervention: CT (computed tomography)
Number of subjects: 140
Study 28188000 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured program for β-blocker titration with up-titration visits every 2 weeks after implantation (target dose: 10mg/day of bisoprolol or 50mg/day of carvedilol).
Number of subjects: 254
Study 28188000 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring for 66 patients in Study Group with daily transmission of weight and blood pressure data.
Number of subjects: 254
Study 28188000 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of the centers (Control Group).
Number of subjects: 254
Study 28188235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis edibles
Number of subjects: 0
Study 28188235 — intervention group
Group type: COMPARATOR
Intervention: Draeger DrugTest
Number of subjects: 0
Study 28188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 326
Study 28188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 326
Study 28188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 326
Study 28188239 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppressant
Number of subjects: 326
Study 28188334 — intervention group
Group type: EXPERIMENTAL
Intervention: AICAR
Number of subjects: 2
Study 28188472 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal PPD and CMP
Number of subjects: 473
Study 28188472 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CMP only
Number of subjects: 473
Study 28188472 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal PPD only
Number of subjects: 473
Study 28188472 — intervention group
Group type: COMPARATOR
Intervention: No maternal depression
Number of subjects: 473
Study 28188565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482
Study 28188565 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 482
Study 28188565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium and Quetiapine (both interventions)
Number of subjects: 482
Study 28188773 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine administration
Number of subjects: 49
Study 28188907 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO6860 (TRPV1 antagonist)
Number of subjects: 64
Study 28189300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 40
Study 28189300 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular pigment optical density (MPOD)
Number of subjects: 40
Study 28189300 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adiposity
Number of subjects: 40
Study 28190158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine mouthwash 20 mg/5 mL four times daily
Number of subjects: 30
Study 28190704 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (photon radiation therapy)
Number of subjects: 76
Study 28190716 — intervention group
Group type: EXPERIMENTAL
Intervention: Aorfix endograft (for highly angulated necks)
Number of subjects: 218
Study 28191026 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g Flaxseed Fiber (FF) with Orlistat
Number of subjects: 38
Study 28191026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg Dairy Calcium (Ca) with Orlistat
Number of subjects: 38
Study 28191026 — intervention group
Group type: COMPARATOR
Intervention: Orlistat alone
Number of subjects: 38
Study 28191034 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatments plus a once-daily multivitamin
Number of subjects: 34
Study 28191034 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin alone (waiting list group)
Number of subjects: 34
Study 28191263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 158
Study 28191263 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation as a coping strategy
Number of subjects: 158
Study 28192114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine (200 mg twice a day)
Number of subjects: 14
Study 28192114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine (400 mg twice a day)
Number of subjects: 14
Study 28192597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg orally and daily on a continuous schedule)
Number of subjects: 19
Study 28193179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (SMK)
Number of subjects: 0
Study 28193179 — intervention group
Group type: COMPARATOR
Intervention: Moist snuff consumption (MSC)
Number of subjects: 0
Study 28193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-assessed physical activity and sedentary behavior
Number of subjects: 7048
Study 28193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls surveillance with monthly calendars and telephone interviews
Number of subjects: 7048
Study 28193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication of incident cardiovascular disease (CVD) events
Number of subjects: 7048
Study 28193515 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 5766
Study 28193515 — intervention group
Group type: COMPARATOR
Intervention: Not exposed to biologics (Control)
Number of subjects: 5766
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir 50 mg/100 mg once daily for 12 weeks
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir 50 mg/100 mg once daily for 12 weeks with ribavirin
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir with ribavirin for 16 or 18 weeks
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir without ribavirin for 16 or 18 weeks
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir for 12 weeks in patients with HCV genotype 1a with baseline RASs
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir for 12 weeks in patients with HCV genotype 1a without baseline RASs
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir and ribavirin for 16 or 18 weeks in patients with HCV genotype 1a with baseline RASs
Number of subjects: 402
Study 28193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir
Number of subjects: 402
Study 28193647 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day dihydroartemisinin-piperaquine (2DP) regimen
Number of subjects: 0
Study 28193647 — intervention group
Group type: COMPARATOR
Intervention: 3-day dihydroartemisinin-piperaquine (3DP) regimen
Number of subjects: 0
Study 28193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization protocol (5.5 hours)
Number of subjects: 330
Study 28193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization protocol
Number of subjects: 330
Study 28193677 — intervention group
Group type: EXPERIMENTAL
Intervention: High Platelet Reactivity (HPR) on clopidogrel (P2Y12 reactivity units >208) in women
Number of subjects: 8448
Study 28193677 — intervention group
Group type: EXPERIMENTAL
Intervention: High Platelet Reactivity (HPR) on clopidogrel (P2Y12 reactivity units >208) in men
Number of subjects: 8448
Study 28193704 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28193717 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial dilated cardiomyopathy (FDCM)
Number of subjects: 870
Study 28193717 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic dilated cardiomyopathy (IDCM)
Number of subjects: 870
Study 28193717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined end point of death or transplantation
Number of subjects: 870
Study 28194012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation levels at the cg07814318 site within the KLF13 gene
Number of subjects: 23
Study 28194012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation levels at the cg07814318 site
Number of subjects: 23
Study 28194012 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of KLF13
Number of subjects: 23
Study 28194229 — intervention group
Group type: EXPERIMENTAL
Intervention: MiR-Test scores
Number of subjects: 202
Study 28194229 — intervention group
Group type: EXPERIMENTAL
Intervention: Free circulating DNA
Number of subjects: 202
Study 28194229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum biomarkers
Number of subjects: 202
Study 28194229 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic mutations in tumours
Number of subjects: 202
Study 28194232 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-challenge OGTT 2 h insulin in CSX
Number of subjects: 237
Study 28194232 — intervention group
Group type: COMPARATOR
Intervention: Post-challenge OGTT 2 h insulin in CAD
Number of subjects: 237
Study 28194232 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy obesity in CAD
Number of subjects: 237
Study 28194232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose, insulin, HOMA-IR in CSX
Number of subjects: 237
Study 28194232 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose, insulin, HOMA-IR in CAD
Number of subjects: 237
Study 28194232 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda index in CSX
Number of subjects: 237
Study 28194232 — intervention group
Group type: COMPARATOR
Intervention: Matsuda index in CAD
Number of subjects: 237
Study 28194232 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c in CSX
Number of subjects: 237
Study 28194232 — intervention group
Group type: COMPARATOR
Intervention: HbA1c in CAD
Number of subjects: 237
Study 28194281 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact between father and newborn
Number of subjects: 83
Study 28194281 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 83
Study 28194306 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) plus integrated program (IP)
Number of subjects: 131
Study 28194306 — intervention group
Group type: COMPARATOR
Intervention: Integrated program (IP) alone
Number of subjects: 131
Study 28194539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimasertib (45 mg/day) plus Temsirolimus (25 mg/week)
Number of subjects: 33
Study 28196056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX; Ozurdex 700 μg) administered immediately after cataract surgery
Number of subjects: 24
Study 28196257 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling system
Number of subjects: 122
Study 28196257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scalp cooling)
Number of subjects: 122
Study 28196270 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly
Number of subjects: 64
Study 28196343 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused children
Number of subjects: 78
Study 28196343 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-abused children)
Number of subjects: 78
Study 28196509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemochron® Signature POCT for PT/INR and ACT+
Number of subjects: 68
Study 28196509 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity
Number of subjects: 68
Study 28196715 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed oral cholera vaccine (OCV), Shanchol™
Number of subjects: 138
Study 28196715 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed to OCV)
Number of subjects: 138
Study 28196730 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Lens (CL)
Number of subjects: 70
Study 28196730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular Lens (IOL)
Number of subjects: 70
Study 28196730 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional surgery to clear visual axis
Number of subjects: 70
Study 28196730 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 70
Study 28196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning hypertension without nocturnal hypertension (subtype II)
Number of subjects: 1070
Study 28196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning hypertension with nocturnal hypertension (subtype III)
Number of subjects: 1070
Study 28196818 — intervention group
Group type: COMPARATOR
Intervention: Morning normotension (subtype I)
Number of subjects: 1070
Study 28196905 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP107, a novel oral paclitaxel formulation, 200 mg/m
Number of subjects: 17
Study 28196905 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP107, a novel oral paclitaxel formulation, 150-250 mg/m
Number of subjects: 17
Study 28196961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic sampling (protected specimen brushings and bronchoalveolar lavages)
Number of subjects: 8
Study 28196961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavages (BAL)
Number of subjects: 8
Study 28196961 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected specimen brushings (PSB)
Number of subjects: 8
Study 28196961 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscope contamination control specimens
Number of subjects: 8